Bortezomib generic versus original

Comparison of Efficacy and Safety between the Original and a Generic Bortezomib in Multiple myeloma patient

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210927006

Enrollment

100

Registered

2021-09-27

Start date

2021-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma requiring treatment patients who were treated with bortezomib based regimen. multiple myeloma, bortezomib, generic bortezomib, original bortezomib

Interventions

MM patients received original bortezomib,MM patients received generic bortezomib

Treatment,Treatment

Original bortezomib patients,Generic bortezomib patients

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed as multiple myeloma according to International Myeloma Working Group 2014 criteria 2) Performance status Estern Cooperative Oncology Group (ECOG) <3 3) Patients were treated with bortezomib-base regimen in the induction phase

Exclusion criteria

Exclusion criteria: Lack of information

Design outcomes

Primary

Measure	Time frame
progression free survival rate 2 years Progression or death	—

Secondary

Measure	Time frame
Overall response rate after induction 4 cycles Rate of response	—

Countries

Thailand

Contacts

Public ContactChutima Kunacheewa

Division of Hematology, Department of Medicine, Siriraj Hospital, Mahidol university

chutima.kua@mahidol.ac.th024194449

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026